Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05873686 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Start date: October 26, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.

NCT ID: NCT05872867 Recruiting - Colorectal Cancer Clinical Trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).

NCT ID: NCT05868174 Recruiting - Clinical trials for Advanced Solid Tumor

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

NCT ID: NCT05867251 Recruiting - Clinical trials for Advanced Solid Tumor

Study of AVZO-021 in Patients With Advanced Solid Tumors

Start date: August 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

NCT ID: NCT05864144 Recruiting - Breast Cancer Clinical Trials

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Start date: May 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

NCT ID: NCT05841563 Recruiting - Clinical trials for Advanced Solid Tumor

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - expansion) will be to evaluate the antitumor activity of PM54 in terms of clinical benefit (response or stable disease [SD] ≥4 months associated with tumor shrinkage), according to the RECIST v.1.1 and/or serum markers as appropriate, in patients with selected advanced solid tumors.

NCT ID: NCT05840835 Recruiting - Clinical trials for Advanced Solid Tumor

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

IMMINENT-01
Start date: February 3, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.

NCT ID: NCT05837299 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of IMC008 for Advanced Solid Tumors

Start date: April 2, 2023
Phase: Phase 1
Study type: Interventional

An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.

NCT ID: NCT05836948 Not yet recruiting - Clinical trials for Advanced Solid Tumor

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

NCT ID: NCT05831995 Recruiting - Clinical trials for Advanced Solid Tumor

Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Start date: March 30, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.